The US Food and Drug Administration (FDA) recently approved the oral Bruton tyrosine kinase (BTK) inhibitor ibrutinib for the
treatment of patients with relapsed or refractory marginal zone lymphoma who require
systemic therapy and have had at least one
prior anti-CD20 therapy.